Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy bluebird bio (BLUE) stocks in Canada

Learn how to easily invest in bluebird bio stocks.

bluebird bio is a biotechnology business based in the US. bluebird bio stocks (BLUE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $30.43 – a decrease of 20.62% over the previous week. bluebird bio employs 1,201 staff and has a trailing 12-month revenue of around $53.7 million.

How to buy shares in bluebird bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLUE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

bluebird bio stock price (NASDAQ:BLUE)

Use our graph to track the performance of BLUE stocks over time.

bluebird bio shares at a glance

Information last updated 2022-01-17.
Latest market close$6.93
52-week range$8.12 - $32.51
50-day moving average $10.49
200-day moving average $14.97
Wall St. target price$13.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-12.83

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy bluebird bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

bluebird bio price performance over time

Historical closes compared with the close of $6.93 from 2022-01-20

1 week (2022-01-13) -18.66%
1 month (2021-12-17) -34.75%
3 months (2021-10-21) -66.01%
6 months (2021-07-21) -74.79%
1 year (2021-01-21) -85.20%
2 years (2020-01-21) -92.76%
3 years (2019-01-18) 129.8955
5 years (2017-01-20) 65.3675

Is bluebird bio under- or over-valued?

Valuing bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

bluebird bio's PEG ratio

bluebird bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into bluebird bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

bluebird bio financials

Revenue TTM $53.7 million
Gross profit TTM $-342,618,000
Return on assets TTM -32.67%
Return on equity TTM -72.21%
Profit margin 0%
Book value $12.42
Market capitalisation $612 million

TTM: trailing 12 months

bluebird bio share dividends

We're not expecting bluebird bio to pay a dividend over the next 12 months.

Have bluebird bio's shares ever split?

bluebird bio's shares were split on a 1544:1000 basis on 5 November 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1544 shares. This wouldn't directly have changed the overall worth of your bluebird bio shares – just the quantity. However, indirectly, the new 35.2% lower share price could have impacted the market appetite for bluebird bio shares which in turn could have impacted bluebird bio's share price.

bluebird bio share price volatility

Over the last 12 months, bluebird bio's shares have ranged in value from as little as $8.12 up to $32.5098. A popular way to gauge a stock's volatility is its "beta".

BLUE.US volatility(beta: 1.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while bluebird bio's is 1.6102. This would suggest that bluebird bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

bluebird bio overview

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc. , Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc. , Gritstone Oncology, Inc.

Stocks similar to bluebird bio

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site